Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Jan 20

PMID 33467114

Citations 15

Authors

Kenichiro Murayama

Michiaki Okada

Kenichi Tanaka

Chika Inadomi

Wataru Yoshioka

Yoshihito Kubotsu

Tomomi Yada

Hiroshi Isoda

Takuya Kuwashiro

Satoshi Oeda

Takumi Akiyama

Noriko Oza

Hideyuki Hyogo

Masafumi Ono

Takumi Kawaguchi

Takuji Torimura

Keizo Anzai

Yuichiro Eguchi

Hirokazu Takahashi

Affiliations

Soon will be listed here.

Abstract

Access to imaging is limited for diagnosing nonalcoholic fatty liver disease (NAFLD) in general populations. This study evaluated the diagnostic performance of noninvasive and nonimaging indexes to predict NAFLD in the general Japanese population. Health checkup examinees without hepatitis virus infection or habitual alcohol drinking were included. Fatty liver was diagnosed by ultrasonography. The hepatic steatosis index (HSI), Zhejiang University (ZJU) index, and fatty liver index (FLI) were determined, and risk of advanced liver fibrosis was evaluated by the fibrosis-4 index. NAFLD was diagnosed in 1935 (28.0%) of the 6927 subjects. The area under the receiver operating characteristic (AUROC) curve of the HSI, ZJU index, and FLI was 0.874, 0.886, and 0.884, respectively. The AUROC of the ZJU index ( < 0.001) and FLI ( = 0.002) was significantly greater than that for the HSI. In subjects with a high risk of advanced fibrosis, the sensitivity of the HSI, ZJU index, and FLI were 88.8%, 94.4%, and 83.3% with a low cut-off value and the specificity was 98.5%, 100%, and 100% with a high cut-off value. In conclusion, all indexes were useful to diagnose NAFLD in the general Japanese population and in subjects with potentially advanced liver fibrosis.

Citing Articles

Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults.

Kim Y, Lee T, Oh C BMC Gastroenterol. 2025; 25(1):110.

PMID: 39994673 PMC: 11853905. DOI: 10.1186/s12876-025-03687-4.

Association between surrogate indices of fatty liver and the risk of colorectal cancer: a cross-sectional United States study.

Shi C, Yuan C, Hao Y, Zhou Z, Zhang Y Transl Cancer Res. 2025; 14(1):313-326.

PMID: 39974378 PMC: 11833385. DOI: 10.21037/tcr-24-1444.

High levels of serum dihomo-γ-linolenic acid are associated with non-alcoholic fatty liver disease in type 2 diabetic patients.

Mochizuki K, Higa M, Ikehara K, Ichijo T, Hirose T Diabetol Int. 2025; 16(1):107-114.

PMID: 39877445 PMC: 11769884. DOI: 10.1007/s13340-024-00760-3.

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.

Kitsunai H, Shinozaki Y, Furusawa S, Kitao N, Ito M, Kurihara H Pharmaceuticals (Basel). 2025; 18(1.

PMID: 39861190 PMC: 11769496. DOI: 10.3390/ph18010129.

Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.

Miwa T, Tajirika S, Imamura N, Adachi M, Horita R, Hanai T JGH Open. 2024; 8(6):e13110.

PMID: 38895100 PMC: 11183927. DOI: 10.1002/jgh3.13110.

References

Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95. DOI: 10.1007/s00535-012-0533-z. View

Yang B, Wu W, Fang K, Wang Y, Huo T, Huang Y . External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015; 10(3):e0120443. PMC: 4363626. DOI: 10.1371/journal.pone.0120443. View

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G . Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008; 19(8):1564-70. PMC: 2488256. DOI: 10.1681/ASN.2007101155. View

Davyduke T, Tandon P, Al-Karaghouli M, Abraldes J, Ma M . Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. Hepatol Commun. 2019; 3(10):1322-1333. PMC: 6771169. DOI: 10.1002/hep4.1411. View

Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O . Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018; 48(10):821-828. DOI: 10.1111/hepr.13179. View

Takahashi H, Ono M, Hyogo H, Tsuji C, Kitajima Y, Ono N . Biphasic effect of alcohol intake on the development of fatty liver disease. J Gastroenterol. 2015; 50(11):1114-23. DOI: 10.1007/s00535-015-1058-z. View

Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H . Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012; 12:2. PMC: 3266187. DOI: 10.1186/1471-230X-12-2. View

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T . The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102(12):2708-15. DOI: 10.1111/j.1572-0241.2007.01526.x. View

10.

Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H . Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2015; 150(3):626-637.e7. DOI: 10.1053/j.gastro.2015.11.048. View

11.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

12.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

13.

Tada T, Iijima H, Kobayashi N, Yoshida M, Nishimura T, Kumada T . Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. Ultrasound Med Biol. 2019; 45(10):2679-2687. DOI: 10.1016/j.ultrasmedbio.2019.05.033. View

14.

Chen L, Huang P, Chien C, Lin C, Chien R . A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease. J Formos Med Assoc. 2019; 119(1 Pt 1):173-181. DOI: 10.1016/j.jfma.2019.03.016. View

15.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

16.

Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R . Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54(12):3541-6. DOI: 10.2337/diabetes.54.12.3541. View

17.

Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N . Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res. 2013; 44(12):1196-207. DOI: 10.1111/hepr.12293. View

18.

Rinella M, Tacke F, Sanyal A, Anstee Q . Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019; 71(4):823-833. DOI: 10.1016/j.jhep.2019.04.019. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View